Cerebrospinal fluid-based biomarkers for amyotrophic lateral sclerosis

Robert Bowser, James Connor and Martin Turner

in Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias

Published on behalf of Oxford University Press

Published in print October 2012 | ISBN: 9780199590674
Published online November 2012 | e-ISBN: 9780191753466 | DOI:
Cerebrospinal fluid-based biomarkers for amyotrophic lateral sclerosis

Show Summary Details


In conclusion, the last decade has seen tremendous advancements in biomarker discovery and validation in neurological disorders. While hypothesis-driven biomarker discovery efforts based on presumed mechanisms relevant to ALS have continued to make important contributions, the use of unbiased biomarker discovery efforts has led to new candidate biomarkers and opportunities. To date, the CSF-based biomarkers best verified in ALS include those related to axonal injury and inflammation. It is likely that for a heterogeneous disease such as ALS a multiprotein panel will be required to classify ALS from control groups and to monitor disease progression. We look forward to translation of validated biomarkers into the clinic to aid physicians in early diagnosis and improved methods to monitor disease progression and drug response.

Chapter.  6323 words.  Illustrated.

Subjects: Neurology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.